Levonorgestrel-releasing intra-uterine systems as female contraceptives

Giovanni Grandi, Grandi G, Antonino Farulla, Filomena Giulia Sileo, Fabio Facchinetti, Facchinetti F
Expert opinion on pharmacotherapy · 2018 · vol. 19(7) , pp. 677–686 · doi:10.1080/14656566.2018.1462337 · PMID:29637798 · W2800833563
Review OA: green CC0 ⤵ 5 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review examines available levonorgestrel-releasing intrauterine systems (LNG-IUSs) for contraception, efficacy, tolerability, and specific indications for 13.5, 19.5, and 52 mg devices.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. AREAS COVERED: The authors provide a narrative review of the LNG-IUSs currently available worldwide as female contraceptives (LNG-IUS 13.5, 19.5 and 52 mg). Specific features of the devices and their parameters of efficacy and tolerability were considered as outcomes. EXPERT OPINION: The one-handed 3.8-mm-diameter inserter of LNG-IUS 13.5 mg and 19.5 mg may be particularly suitable in nulliparous women. While LNG-IUSs 13.5, 19.5 mg and LNG 52 mg should be used by women simply looking for an effective contraceptive method for up to 3, 4 or 5 years, LNG-IUS 52 mg has also been approved for the treatment of heavy menstrual bleeding and endometrial protection during hormone replacement therapy. LNG-IUS 52 mg is ideal for women who are experiencing a certain hyperestrogenic hormonal environment, with heavy menstrual bleeding due to hormonal imbalances, adenomyosis or fibroids, in the case of symptomatic endometriosis or for endometrial protection during hormone estrogenic replacement therapy in non-hysterectomized women.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Contraceptive Agents, Female Intrauterine Devices, Medicated Levonorgestrel Contraceptive Agents, Female Contraceptive Agents, Female Contraceptive Agents, Female Contraceptive Agents, Female Female Female Humans Humans Intrauterine Devices, Medicated Intrauterine Devices, Medicated Levonorgestrel Levonorgestrel Levonorgestrel Levonorgestrel

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (80)

Cited by (5)

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:21:50.425981+00:00
License: CC0 · commercial use OK